PMID- 33525583
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 3
DP  - 2021 Jan 28
TI  - Toxicity Reduction after Craniospinal Irradiation via Helical Tomotherapy in 
      Patients with Medulloblastoma: A Unicentric Retrospective Analysis.
LID - 10.3390/cancers13030501 [doi]
LID - 501
AB  - Objectives: Recent trials with craniospinal irradiation (CSI) via helical 
      Tomotherapy (HT) demonstrated encouraging medulloblastoma results. In this study, 
      we assess the toxicity profile of different radiation techniques and estimate 
      survival rates. Materials and Methods: We reviewed the records of 46 patients who 
      underwent irradiation for medulloblastoma between 1999 and 2019 (27 conventional 
      radiotherapy technique (CRT) and 19 HT). Patient, tumor, and treatment 
      characteristics, as well as treatment outcomes-local control rate (LCR), 
      event-free survival (EFS), and overall survival (OS)-were reviewed. Acute and 
      late adverse events (AEs) were evaluated according to the Radiation Therapy 
      Oncology Group and the European Organization for Research and Treatment of Cancer 
      (RTOG/EORTC) criteria. Results: In total, 43 courses of CSI and three local RT 
      were administered to the 46 patients: 30 were male, the median age was 7 years 
      (range 1-56). A median total RT dose of 55 Gy (range 44-68) and a median CSI dose 
      of 35 Gy (range, 23.4-40) was delivered. During follow-up (median, 99 months), 
      six patients (13%) developed recurrence. The EFS rate after 5 years was 84%. The 
      overall OS rates after 5 and 10 years were 95% and 88%, respectively. There were 
      no treatment-related deaths. Following HT, a trend towards lower grade 2/3 acute 
      upper gastrointestinal (p = 0.07) and subacute CNS (p = 0.05) toxicity rates was 
      detected compared to CRT-group. The risk of late CNS toxicities, mainly grade 
      2/3, was significantly lower following HT technique (p = 0.003). Conclusion: CSI 
      via HT is an efficacious treatment modality in medulloblastoma patients. In all, 
      we detected a reduced rate of several acute, subacute, and chronic toxicities 
      following HT compared to CRT.
FAU - Oztunali, Anil
AU  - Oztunali A
AD  - Radiation Oncology Department, University Hospital Muenster, 48149 Muenster, 
      Germany.
FAU - Elsayad, Khaled
AU  - Elsayad K
AUID- ORCID: 0000-0001-9303-7336
AD  - Radiation Oncology Department, University Hospital Muenster, 48149 Muenster, 
      Germany.
FAU - Scobioala, Sergiu
AU  - Scobioala S
AD  - Radiation Oncology Department, University Hospital Muenster, 48149 Muenster, 
      Germany.
FAU - Channaoui, Mohammed
AU  - Channaoui M
AD  - Radiation Oncology Department, University Hospital Muenster, 48149 Muenster, 
      Germany.
FAU - Haverkamp, Uwe
AU  - Haverkamp U
AD  - Radiation Oncology Department, University Hospital Muenster, 48149 Muenster, 
      Germany.
FAU - Grauer, Oliver
AU  - Grauer O
AD  - Neuro-Oncology Department, University Hospital Muenster, 48149 Muenster, Germany.
FAU - Strater, Ronald
AU  - Strater R
AD  - Pediatric Oncology Department, University Hospital Muenster, 48149 Muenster, 
      Germany.
FAU - Brentrup, Angela
AU  - Brentrup A
AD  - Department of Neurosurgery, University Hospital Muenster, 48149 Muenster, 
      Germany.
FAU - Stummer, Walter
AU  - Stummer W
AD  - Department of Neurosurgery, University Hospital Muenster, 48149 Muenster, 
      Germany.
FAU - Kerl, Kornelius
AU  - Kerl K
AD  - Pediatric Oncology Department, University Hospital Muenster, 48149 Muenster, 
      Germany.
FAU - Eich, Hans Theodor
AU  - Eich HT
AD  - Radiation Oncology Department, University Hospital Muenster, 48149 Muenster, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20210128
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7865289
OTO - NOTNLM
OT  - Tomotherapy
OT  - conventional
OT  - intensity-modulated
OT  - toxicity
COIS- The authors declare no conflict of interest.
EDAT- 2021/02/03 06:00
MHDA- 2021/02/03 06:01
PMCR- 2021/01/28
CRDT- 2021/02/02 01:03
PHST- 2020/12/23 00:00 [received]
PHST- 2021/01/25 00:00 [revised]
PHST- 2021/01/26 00:00 [accepted]
PHST- 2021/02/02 01:03 [entrez]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2021/02/03 06:01 [medline]
PHST- 2021/01/28 00:00 [pmc-release]
AID - cancers13030501 [pii]
AID - cancers-13-00501 [pii]
AID - 10.3390/cancers13030501 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Jan 28;13(3):501. doi: 10.3390/cancers13030501.